Literature DB >> 11170729

Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat.

J A Plunkett1, C G Yu, J M Easton, J R Bethea, R P Yezierski.   

Abstract

Intraspinal injection of quisqualic acid (QUIS) produces excitotoxic injury with pathophysiological characteristics similar to those associated with ischemic and traumatic spinal cord injury (SCI). Responses to QUIS-induced injury include an inflammatory component, as well as the development of spontaneous and evoked pain behaviors. We hypothesized that QUIS-induced inflammation and subsequent gene expression contribute to the development and progression of pain-related behaviors and that blockade of inflammation-related gene expression leads to the amelioration of these behaviors. Using the QUIS model of spinal cord injury, we examined whether interleukin-10 (IL-10), a potent anti-inflammatory cytokine, is able to reduce mRNA levels of inflammatory and cell death-related genes leading to a reduction of pain behaviors. The results demonstrate that animals receiving systemic injection of IL-10, 30 minutes following QUIS-induced SCI, showed a significant delay in the onset of excessive grooming behavior, a significant reduction in grooming severity, and a significant reduction in the longitudinal extent of a pattern of neuronal loss within the spinal cord characterized as "grooming-type damage." QUIS injections also resulted in an increase in mRNA levels of interleukin-1 beta (IL-1 beta), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), CD95 ligand (CD95-L, also called FAS-L/APO-1L), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Results of QUIS injury plus IL-10 treatment resulted in a significant downregulation of IL1-beta and iNOS mRNA and these results were supported by Western blot analysis of protein levels following IL-10 treatment. These data suggest that IL-10 reduces inflammation and that targeting injury-induced inflammation is an effective strategy for limiting the extent of neuronal damage following excitotoxic SCI and thus the onset and progression of injury-induced pain behaviors. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170729     DOI: 10.1006/exnr.2000.7604

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  63 in total

1.  Herpes simplex virus vector-mediated expression of interleukin-10 reduces below-level central neuropathic pain after spinal cord injury.

Authors:  Darryl Lau; Steven E Harte; Thomas J Morrow; Shiyong Wang; Marina Mata; David J Fink
Journal:  Neurorehabil Neural Repair       Date:  2012-05-15       Impact factor: 3.919

2.  Anti-CD11d integrin antibody treatment restores normal serotonergic projections to the dorsal, intermediate, and ventral horns of the injured spinal cord.

Authors:  Mark A Oatway; Yuhua Chen; Jamie C Bruce; Gregory A Dekaban; Lynne C Weaver
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

3.  Evaluation of the pathologic characteristics of excitotoxic spinal cord injury with MR imaging.

Authors:  Sara A Berens; Daniel C Colvin; Chen-Guang Yu; Robert P Yezierski; Thomas H Mareci
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

4.  Inhibition of NOX2 signaling limits pain-related behavior and improves motor function in male mice after spinal cord injury: Participation of IL-10/miR-155 pathways.

Authors:  Boris Sabirzhanov; Yun Li; Marino Coll-Miro; Jessica J Matyas; Junyun He; Alok Kumar; Nicole Ward; Jingwen Yu; Alan I Faden; Junfang Wu
Journal:  Brain Behav Immun       Date:  2019-02-23       Impact factor: 7.217

5.  Rapid induction of genes associated with tissue protection and neural development in contused adult spinal cord after radial glial cell transplantation.

Authors:  Yu-Wen Chang; Loyal A Goff; Hedong Li; Noriko Kane-Goldsmith; Evangeline Tzatzalos; Ronald P Hart; Wise Young; Martin Grumet
Journal:  J Neurotrauma       Date:  2009-07       Impact factor: 5.269

Review 6.  Glia in pathological pain: a role for fractalkine.

Authors:  E D Milligan; E M Sloane; L R Watkins
Journal:  J Neuroimmunol       Date:  2008-06-10       Impact factor: 3.478

Review 7.  Long-term control of neuropathic pain in a non-viral gene therapy paradigm.

Authors:  E M Sloane; R G Soderquist; S F Maier; M J Mahoney; L R Watkins; E D Milligan
Journal:  Gene Ther       Date:  2009-03-05       Impact factor: 5.250

Review 8.  Microglial phenotype and adaptation.

Authors:  B J L Eggen; D Raj; U-K Hanisch; H W G M Boddeke
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-25       Impact factor: 4.147

9.  Metabolomics uncovers dietary omega-3 fatty acid-derived metabolites implicated in anti-nociceptive responses after experimental spinal cord injury.

Authors:  J D Figueroa; K Cordero; M Serrano-Illan; A Almeyda; K Baldeosingh; F G Almaguel; M De Leon
Journal:  Neuroscience       Date:  2013-09-14       Impact factor: 3.590

10.  Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain.

Authors:  E Sloane; S Langer; B Jekich; J Mahoney; T Hughes; M Frank; W Seibert; G Huberty; B Coats; J Harrison; D Klinman; S Poole; S Maier; K Johnson; R Chavez; L R Watkins; L Leinwand; E Milligan
Journal:  Gene Ther       Date:  2009-07-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.